Nipro 8086.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 8086.T. It has been listed since 1 February 1987. In the fiscal year to 31 March 2026, it reported revenue of ¥660.54bn and net income of ¥13.50bn. At that date it held total assets of ¥1.21trn and shareholders' equity of ¥274.12bn.

Nipro Corp. engages in the manufacture and sale of medical equipment, pharmaceutical products, and glass products. The company is headquartered in Osaka, Osaka-Fu. The firm has three segments. The Medical-Related segment involves in the sale of injections and infusions, artificial organs, high function and dialysis related medical equipment, and diabetes, generics and kits related medicine products in Japan, as well as the sales of medical devices for injection and infusion, artificial organs and diabetes in overseas markets. The Pharmaceutical-Related segment involves in the manufacture and sale of pharmaceuticals. The Pharma Packaging segment sells glass for vials and ampoules as medical glass in Japan, thermos glass for lighting and glass for lighting equipment.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Yoshihiko SanoPresident, Representative Director, since 2000
• Mr. Takehito YogoSenior Managing Director, Chief Director of Administration Supervision & Management Planning, since 2018
• Mr. Yasushi OhyamaSenior Managing Director, Director of Vascular Business, President of Subsidiary, since 2013
• Mr. Tsuyoshi YamazakiSenior Managing Director, Director of International Business and International Business Supervision, President of Subsidiary, since 2009
• Mr. Kiyotaka YoshiokaSenior Managing Director, Director of Domestic Business in Domestic Business Supervision, since 2006
• Mr. Kyoetsu KobayashiManaging Director, Chief Director of Stable Production and Crisis Administration, since 2009
• Mr. Toshiaki MasudaManaging Director, Senior Chief Director of Planning & Development Technology, Director of General Research Institute,, since 2008
• Mr. Kimihito MinouraManaging Director, Chief Director of Business Promotion, Chief Director of Business Administration, Chief Director of New Business Development, Director of Regenerative Medicine Business,, since 2009
• Mr. Kenichi NishidaManaging Director, Senior Chief Director of Pharmaceutical Production, Director of Pharmaceutical Business, President of Subsidiary, since 2010
• Mr. Kazuhiko SanoManaging Director, Chief Director of Facilities, Manager of Production Technology Center, since 2010
• Mr. Takashi GotoExecutive Officer , Deputy Chief Director of Domestic Business in Main Medical Sales Unit, Director of Business Strategy Office, Team Leader of Regional Medical Collaboration Team
• Mr. Keizo MaruyamaExecutive Officer, Chief Director of Domestic Business in Main Domestic Product Development/Technical Sales Unit

Overall

61

Environment

44

Social

99

Governance

41

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.